Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Identification of novel pRb binding sites using CpG microarrays suggests that E2F recruits pRb to specific genomic sites during S phase

Abstract

The retinoblastoma (Rb) tumor suppressor protein is an important regulator of cell proliferation and differentiation. Many studies have shown that pRb can negatively regulate the activity of the E2F family of transcription factors during G0 and G1 phases of the cell cycle, perhaps by serving as a bridge between the E2Fs and transcriptional repressors such as histone deacetylases and methylases. However, pRb has also been shown to localize to discrete DNA foci during S phase, a time at which pRb is thought to be dissociated from E2F. Numerous other DNA binding proteins have been shown to interact with pRb, suggesting that pRb may control progression through S phase by binding to sites in the genome distinct from E2F target gene promoters. To test this hypothesis, we have identified novel pRb binding sites within the human genome using an unbiased approach which relies upon a combination of chromatin immunoprecipitation and CpG microarray analysis. To provide the greatest opportunity of finding distinct sets of pRb binding sites, we examined pRb binding in chromatin obtained from human Raji cells synchronized in either G0/G1 phase or S phase. These experiments have allowed us to identify a large set of new genomic binding sites for the pRb protein. We found that some sites are occupied by pRb only during G0/G1 phase, as would be predicted from previous models of pRb function. We also identified sites to which pRb bound only during S phase and other sites which were bound constitutively by pRb. Surprisingly, we found that E2F1 was present at most of the CpG islands bound by pRb, independent of the phase of the cell cycle. Thus, although pRb has the potential to interact with numerous transcription factors, our data suggest that the majority of DNA-bound pRb is recruited to E2F target promoters during both G0/G1 and S phases.

This is a preview of subscription content, access via your institution

Access options

Buy this article

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9

Similar content being viewed by others

References

  • Albert T, Wells J, Funk J-O, Pullner A, Raschke E-E, Stelzer G, Meisterernst M, Farnham PJ and Eick D . (2001a). J. Biol. Chem., 276, 20482–20490.

  • Albert T, Wells J, Funk JO, Pullner A, Raschke EE, Stelzer G, Meisterernst M, Farnham PJ and Eick D . (2001b). J. Biol. Chem., 276, 20842–20890.

  • Antequera F and Bird A . (1999). Curr. Biol., 9, R661–R667.

  • Bosco G, Du W and Orr-Weaver TL . (2001). Nat. Cell Biol., 3, 289–295.

  • Boyd KE, Wells J, Gutman J, Bartley SM and Farnham PJ . (1998). Proc. Natl. Acad. Sci. USA, 95, 13887–13892.

  • Carney JP, Maser RS, Olivares H, Davis EM, Le Beau MJ, Yates RI, Hays L, Morgan WF and Petrini JHJ . (1998). Cell, 93, 477–486.

  • Cross SH and Bird AP . (1995). Curr. Opin. Genet. Dev., 5, 309–314.

  • Farnham PJ, Slansky JE and Kollmar R . (1993). Biochim. Biophys. Acta, 1155, 125–131.

  • Goodrich DW, Wang NP, Qian Y-W, Lee EY-H and Lee W-H . (1991). Cell, 67, 293–302.

  • Harbour JW and Dean DC . (2000). Genes Dev., 14, 2393–2409.

  • Helin K, Lees JA, Vidal M, Dyson N, Harlow E and Fattaey A . (1992). Cell, 70, 337–350.

  • Ivey-Hoyle M, Conroy R, Huber HE, Goodhart PJ, Oliff A and Heimbrook DC . (1993). Mol. Cell. Biol., 13, 7802–7812.

  • Kaelin Jr WG, Krek W, Sellers WR, DeCaprio JA, Ajchenbaum F, Fuchs CS, Chittenden T, Li Y, Farnham PJ, Blanar MA, Livingston DM and Flemington EK . (1992). Cell, 70, 351–364.

  • Kennedy BK, Barbie DA, Classon M, Dyson N and Harlow E . (2000). Genes Dev., 14, 2855–2868.

  • Lees JA, Saito M, Vidal M, Valentine M, Look T, Harlow E, Dyson N and Helin K . (1993). Mol. Cell. Biol., 13, 7813–7825.

  • Lipinski MM and Jacks T . (1999). Oncogene, 18, 7873–7882.

  • Ma Y, Croxton R, Moorer RLJ and Cress WD . (2002). Arch. Biochem. Biophys., 399, 212–224.

  • Maser RS, Mirzoeva OK, Wells J, Olivares H, Williams BR, Zinkel R, Farnham PJ and Petrini JHJ . (2001). Mol. Cell. Biol., 21, 6006–6016.

  • Morris EJ and Dyson NJ . (2001a). Adv. Cancer Res., 82, 1–54.

  • Morris EJ and Dyson NJ . (2001b). Adv. Cancer Res., 82, 1–54.

  • Muller H, Bracken AP, Vernell R, Moroni MC, Christians F, Grassilli E, Prosperini E, Vigo E, Oliner JD and Helin K . (2001). Genes Dev., 15, 267–285.

  • Polager S, Kalma Y, Berkovich E and Ginsberg D . (2002). Oncogene, 21, 437–446.

  • Ponzio G, Loubat A, Rochet N, Turchi L, Rezzonico R, Far DF, Dulic V and Rossi B . (1998). Oncogene, 17, 1159–1166.

  • Ren B, Cam H, Takahashi Y, Volkert T, Terragni J, Young RA and Dynlacht BD . (2002). Genes Dev., 16, 245–256.

  • Royzman I, Austin RJ, Bosco G, Bell SP and Orr-Weaver TL . (1999). Genes Dev., 7, 827–840.

  • Sawai M, Takase K, Hirobumi T and Tsukada K . (1990). Exp. Cell Res., 187, 4–10

  • Shan B, Zhu X, Chen P-L, Durfee T, Yang Y, Sharp D and Lee W-H . (1992). Mol. Cell. Biol., 12, 5620–5631.

  • Takahashi Y, Rayman JB and Dynlacht BD . (2000). Genes Dev., 14, 804–816.

  • Thomas DM, Carty SA, Piscopo DM, Lee J-S, Wang W-F, Forrester WC and Hinds PW . (2001). Mol. Cell, 8, 303–316.

  • Trimarchi JM and Lees JA . (2001). Nat. Rev., 3, 11–20.

  • Turner WJ and Woodworth ME . (2001). J. Virol., 75, 5638–5645.

  • Weinberg RA . (1995). Cell, 81, 323–330.

  • Weinmann AS, Bartley SM, Zhang MQ, Zhang T and Farnham PJ . (2001). Mol. Cell. Biol., 21, 6820–6832.

  • Weinmann AS, Yan PS, Oberley MJ, Huang TH-M and Farnham PJ . (2002). Genes Dev., 16, 235–244.

  • Weintraub SJ, Chow KNB, Luo RX, Zhang SH, He S and Dean DC . (1995). Nature, 375, 812–815.

  • Wells J, Boyd KE, Fry CJ, Bartley SM and Farnham PJ . (2000). Mol. Cell Biol., 20, 5797–5807.

  • Wells J and Farnham PJ . (2002). Methods, 26, 48–56.

  • Wells J, Graveel CR, Bartley SM, Madore SJ and Farnham PJ . (2002). Proc. Nat. Acad. Sci. USA, 99, 3890–3895.

  • Yan PS, Chen C-M, Shi H, Rahmatpanah F, Wei SH, Caldwell CW and Huang TH-M . (2001). Cancer Research, 61, 8375–8380.

  • Zhang HS and Dean DC . (2001). Oncogene, 20, 3134–3138.

  • Zwicker J, Liu N, Engeland K, Lucibello FC and Müller R . (1996). Science, 271, 1595–1597.

Download references

Acknowledgements

We thank Sarah Harkins-Perry and Stephanie Bartley for excellent technical assistance, and Dr Dirk Eick for the gift of the Raji cells. We also like to express our thanks to Brad Stewart for sequencing analysis, to the Biotechnology Center for synthesizing all of the primers used in this study and to Kathy Schell, Pam Whitney and Joan Batchelder of the Comprehensive Cancer Center for their expert assistance with flow cytometry analysis. This work was supported in part by Public Health Service grant CA22484 and CA45240 (to PJF), CA1452 (a NCI Cancer Center Core Grant), R33CA84701 (TH–MH), and NIH CA14520-29 (to the Comprehensive Cancer Center).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Peggy J Farnham.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wells, J., Yan, P., Cechvala, M. et al. Identification of novel pRb binding sites using CpG microarrays suggests that E2F recruits pRb to specific genomic sites during S phase. Oncogene 22, 1445–1460 (2003). https://doi.org/10.1038/sj.onc.1206264

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/sj.onc.1206264

Keywords

This article is cited by

Search

Quick links